1-7 of 7
John Nemunaitis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors

Michael S. Gordon, John Nemunaitis, Minal Barve, Zev A. Wainberg, Erika P. Hamilton, Ramesh K. Ramanathan, George W. Sledge, Jr, Huibin Yue, Susan E. Morgan-Lappe, Martha Blaney, Sreeneeranj Kasichayanula, Monica Motwani, Lan Wang, Louie Naumovski, John H. Strickler
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (10): 1988–1995.
https://doi.org/10.1158/1535-7163.MCT-20-0985
Published: 01 October 2021
View article titled, Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors
Open the PDF for Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors in another window
Journal Articles

Abstract A098: Preliminary results from a phase 1/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced malignancies

Mansoor Saleh, Martin Gutierrez, Vivek Subbiah, David C. Smith, Luis Féliz, Huiling Zhen, Tao Ji, John Nemunaitis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A098.
https://doi.org/10.1158/1535-7163.TARG-17-A098
Published: 01 January 2018
View article titled, Abstract A098: Preliminary results from a phase 1/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced malignancies
Journal Articles

Abstract B147: A phase 1 drug-drug interaction study between ixazomib, an oral proteasome inhibitor, and rifampin in patients (pts) with advanced solid tumors

Neeraj Gupta, Michael J. Hanley, Karthik Venkatakrishnan, Alberto Bessudo, Sunil Sharma, Bert O'Neil, Bingxia Wang, Ai-Min Hui, John Nemunaitis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B147.
https://doi.org/10.1158/1535-7163.TARG-15-B147
Published: 01 December 2015
View article titled, Abstract B147: A phase 1 drug-drug interaction study between ixazomib, an oral proteasome inhibitor, and rifampin in patients (pts) with advanced solid tumors
Journal Articles

Abstract B191: Phase 1 pharmacokinetic (PK) assessments of ATI-1123, a novel human serum albumin-stabilized nanoparticle docetaxel liposomal formulation, in patients with advanced solid malignancies.

Devalingam Mahalingam, Alain Mita, Ahmed Kousba, Sushma Vemulapalli, Nicole Gallegos, Gavin Anderson, J. Charles, Jon M. Rogers, John Sarantopoulos, Monica Mita, Neil Senzer, John Nemunaitis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B191.
https://doi.org/10.1158/1535-7163.TARG-11-B191
Published: 12 November 2011
View article titled, Abstract B191: Phase 1 pharmacokinetic (PK) assessments of ATI-1123, a novel human serum albumin-stabilized nanoparticle docetaxel liposomal formulation, in patients with advanced solid malignancies.
Journal Articles

A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of a novel cyclin-dependent kinase inhibitor administered weekly in subjects with advanced malignancies.

Rajat Bannerji, Marc Saltzman, Mitchell Rosenberg, Karen Small, Stuart Black, Paul Kirschmeier, Paul Statkevich, Malaz Abutarif, David Parry, Siu-Long Yao, John Nemunaitis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A117.
Published: 01 November 2007
View article titled, A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of a novel cyclin-dependent kinase inhibitor administered weekly in subjects with advanced malignancies.
Journal Articles

A phase 1 dose escalation study and signs of anti-metastatic activity of ARQ 197, a selective c-Met inhibitor

Lee Rosen, Neil Senzer, John Nemunaitis, Tarek Mekhail, Ronald Bukowski, Chiang Li, Nigel Rulewski, April Dovholuk, Feng Chai, Thomas Chan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B91.
Published: 01 November 2007
View article titled, A phase 1 dose escalation study and signs of anti-metastatic activity of ARQ 197, a selective c-Met inhibitor
Journal Articles

p53 therapy in a patient with Li-Fraumeni syndrome

Neil Senzer, John Nemunaitis, Michael Nemunaitis, Jeffrey Lamont, Martin Gore, Hani Gabra, Rosalind Eeles, Nayanta Sodha, Frank J. Lynch, Louis A. Zumstein, Kerstin B. Menander, Robert E. Sobol, Sunil Chada
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (5): 1478–1482.
https://doi.org/10.1158/1535-7163.MCT-07-0125
Published: 18 May 2007
View article titled, <em>p53</em> therapy in a patient with Li-Fraumeni syndrome
Open the PDF for <em>p53</em> therapy in a patient with Li-Fraumeni syndrome in another window